IntegRAted Chronic Care Program at Specialized AF Clinic Versus Usual CarE in Patients With Atrial Fibrillation - RACE4

Sponsor
Maastricht University Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT01740037
Collaborator
Stichting Achmea Gezondheidszor (Other), DSW (Other), CZ Fonds (Other), Bayer (Industry), Boehringer Ingelheim (Industry), Bristol-Myers Squibb (Industry), Pfizer (Industry), Daiichi Sankyo, Inc. (Industry)
1,375
8
2
69.9
171.9
2.5

Study Details

Study Description

Brief Summary

Rationale: The treatment of patients with atrial fibrillation is often inadequate due to poor guideline adherence. An integrated chronic care program (ICCP) at a specialized AF-clinic was found to be superior to usual care provided by a cardiologist in terms of cardiovascular hospitalizations and cardiovascular mortality.

Hypothesis: treatment at a specialized AF clinic is superior to usual care in terms of cardiovascular mortality and cardiovascular hospitalizations, cost-effectiveness, quality of life and guideline adherence.

Objectives: primary objective is to show that an ICCP reduces cardiovascular hospitalizations and mortality.

Study design: randomized controlled trial with two study arms: usual care provided by cardiologists (control) versus integrated chronic care program at a specialized AF clinic (intervention) in 8 hospitals in the Netherlands. The RACE4 is an event driven study. A total number of 246 events is needed. In total 1716 patients with newly diagnosed AF will be included. Total duration of the study is 5 years and 10 months with a minimal follow up of 1 year. Data is collected at inclusion, after 3, 6, 12 months, every year thereafter and at the end of the study.

Study population: Patients older than 18 year with newly diagnosed AF.

Intervention: The intervention is delivered through the specialized outpatient AF clinic. The multidisciplinary team at the AF clinic consists of a nurse practitioner or physician assistant or specialised cardiovascular nurse, cardiologist, and is guided by guidelines-based decision support software program based on the applicable ESC guideline recommendations. The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP.

Condition or Disease Intervention/Treatment Phase
  • Other: Specialized outpatient AF Clinic
  • Other: Usual Care
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
1375 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
IntegRAted Chronic Care Program at a Specialized Atrial Fibrillation (AF) Clinic Versus Usual CarE in Patients With Atrial Fibrillation, an Investigator-initiated, Prospective, Randomised, Open Label, Blinded Outcome Assessment (PROBE) Controlled Multi-center Study
Actual Study Start Date :
Dec 1, 2012
Actual Primary Completion Date :
Sep 30, 2018
Actual Study Completion Date :
Sep 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Specialized AF-clinic

Management of AF patients in specialized outpatient AF Clinics according to the principles of an integrated chronic care program (ICCP) performed by a nurse practitioner/ physician assistant/ specialised cardiovascular nurse, cardiologist, supported by an ICT decision support tool based on professional guidelines (CardioConsult AF®). The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP. In addition, the intervention is based on identifying risk factors and potential problems in patients, and addressing needs through dynamic use of personalized education and adjustment of treatment.

Other: Specialized outpatient AF Clinic

Active Comparator: Usual Care

Usual care provided by cardiologists at the regular outpatient clinic.

Other: Usual Care

Outcome Measures

Primary Outcome Measures

  1. The primary endpoint is a composite of unplanned admission to the hospital for any cardiovascular reason and cardiovascular death. [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

Secondary Outcome Measures

  1. All components of the primary endpoint [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

  2. All-cause mortality [Minimum of 1 year and a maximum of 5 years and 10 months]

  3. Total number of unplanned all-cause hospitalizations [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

  4. Duration of unplanned all-cause hospitalizations [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

  5. Total number of unplanned cardiovascular hospitalizations [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

  6. Duration of unplanned cardiovascular hospitalizations [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

  7. Total number of unplanned hospitalizations related to atrial fibrillation [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

  8. Duration of unplanned hospitalizations related to atrial fibrillation [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

  9. Recurrent unplanned cardiovascular hospitalizations [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

  10. Costs and cost-effectiveness [baseline, 1 year, 2 years, 3 years]

    Costs, Quality Adjusted Life Years (QALYs) and Cost-effectiveness (Incremental Cost-Effectiveness Ratio - ICER)

  11. Implementation of care [Follow up with minimum of 1 year and a maximum of 5 years and 10 months]

    The extent to which the comprehensive cardiovascular treatment is in accordance with the most recent ESC guidelines Management of Atrial Fibrillation, the HF guidelines of acute and chronic heart failure and the CVD prevention guidelines

  12. Patient Quality of life [Baseline, 1 year, 2 years, 3 years]

    General health-related QoL is measured by using the SF-36

  13. Patient Quality of life [Baseline, 1 year, 2 years, 3 years]

    Patient's perception of severity of arrhythmia-related symptoms is measured by using the AFSS

  14. Anxiety and/ or depression [Baseline, 1 year, 2 years, 3 years]

    HADS-NL

  15. Knowledge of AF [Baseline, 1 year, 2 years, 3 years]

    Netherlands Knowledge Scale on AF

  16. Compliance to medication [Baseline, 1 year, 2 years, 3 years]

    MMAS

  17. Compliance to medication [Baseline, 1 year, 2 years, 3 years]

    To measure the level of activation of a specific individual the PAM-13 Dutch is used

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients with newly diagnosed AF detected on electrocardiogram (ECG), holter recordings or event recorder with a duration > 30 seconds, 3 months before inclusion or

  2. Patients with a history of diagnosed AF, with no regular control at a cardiologist for AF in the last 2 years and referred by a (non-)cardiologic medical specialist for new diagnostics or therapeutic issue;

  3. Age ≥18 years.

Exclusion Criteria:
  1. No electrocardiographic objectified AF;

  2. Unstable heart failure defined as NYHA IV or heart failure necessitating hospital admission < 3 months before inclusion;

  3. Acute coronary syndrome (acute myocardial infarction or instable angina pectoris, with two of the following characteristics: chest pain and/ or ischemic electrocardiographic changes, and/ or cardiac enzyme rise) < 3 months before inclusion;

  4. Untreated hyperthyroidism or < 3 months euthyroidism before inclusion;

  5. Foreseen pacemaker, internal cardioverter defibrillator, and/ or cardiac resynchronization therapy;

  6. Cardiac surgery ≤ 3 months before inclusion;

  7. Planned cardiac surgery;

  8. Regular control and treatment, also for AF, at another specialized outpatient cardiac clinic;

  9. Patient is not able to fill in the questionnaires;

  10. Participation in other clinical study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Martini Ziekenhuis Groningen Netherlands
2 UMCG Groningen Netherlands
3 Spaarne Gasthuis Haarlem Netherlands
4 Medisch Centrum Leeuwarden Leeuwarden Netherlands
5 MUMC+ Maastricht Netherlands
6 Canisius Wilhelmina Ziekenhuis Nijmegen Nijmegen Netherlands
7 Zaans Medisch Centrum Zaandam Netherlands
8 Isala Zwolle Netherlands

Sponsors and Collaborators

  • Maastricht University Medical Center
  • Stichting Achmea Gezondheidszor
  • DSW
  • CZ Fonds
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Pfizer
  • Daiichi Sankyo, Inc.

Investigators

  • Principal Investigator: H.J.G.M. Crijns, prof. dr., Maastricht University Medical Center
  • Principal Investigator: I.C. Van Gelder, prof. dr., UMCG
  • Principal Investigator: R.G. Tieleman, dr., Martini Ziekenhuis

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01740037
Other Study ID Numbers:
  • METC 11-2-099
First Posted:
Dec 4, 2012
Last Update Posted:
May 28, 2019
Last Verified:
Apr 1, 2019
Keywords provided by Maastricht University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 28, 2019